Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes

Table 2 Clinical characteristics of patients with type 2 diabetes between the improved/stable and worsened glycemic control after switching from vildagliptin to omarigliptin

	Improved/stable (n = 5)	Worsened (n = 10)	P value
Male : Female	4 : 1	9 : 1	NS
Age (yr)	67.8 ± 10.2	71.2 ± 8.1	NS
Duration (yr)	9.8 ± 4.1	14.5 ± 4.5	NS
BMI (kg/m2)	25.1 ± 4.3	23.0 ± 2.8	NS
eGFR (mL/min/1.73 m2)	71.2 ± 19.2	59.4 ± 12.9	NS
HbA1c (%)	7.48 ± 0.97	6.97 ± 0.41	NS
Metformin use	2 (40%)	4 (40%)	NS
Insulin secretagogues1 use	3 (60%)	5 (50%)	NS
Insulin use	2 (40%)	1 (10%)	NS

¹Insulin secretagogues include sulfonylurea and glinide but not dipeptidyl peptidase-4 inhibitor.

Data are shown as mean ± SD or n (%) unless otherwise indicated. BMI: Body mass index; eGFR: Estimated glomerular filtration rate; HbA1c: Hemoglobin A1c; NS: Not significant.